Skip to Main Content

Advertisement

Skip Nav Destination

Abstract CT537: A phase 2, multicenter, randomized, double-blind trial of maintenance therapy with FLT3 inhibitor gilteritinib (ASP2215) in patients with FLT3/ITD AML (GOSSAMER study)

Cancer Res (2022) 82 (12_Supplement): CT537.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal